Tag: stock

NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.

SINGAPORE, June 04, 2025 (GLOBE NEWSWIRE) -- MoneyHero Limited (NASDAQ: MNY) (MoneyHero” or the “Company”), a leading personal finance aggregation and comparison platform, as well as a digital insurance brokerage provider in Greater Southeast Asia, today announced a strategic partnership with Rizal Commercial Banking Corporation (“RCBC”), a trusted leader in Philippine banking known for its customer-focused innovation and inclusive financial services, through its card servicing entity, RCBC Bankard Services Corporation (“RCBC Credit Cards”). Through this collaboration, MoneyHero will integrate RCBC’s full suite of rewards, lifestyle, travel, and premium credit card products into its digital platform, enabling Filipinos to seamlessly discover, compare, and apply for cards that suit their personal financial needs.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cerevel Therapeutics Holdings, Inc. (CERE) on behalf of long-term stockholders following a class action complaint that was filed against Cerevel on April 3, 2025 with a Class Period from October 11, 2023 through August 1, 2024. Our investigation concerns whether the board of directors of Cerevel have breached their fiduciary duties to the company.

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Tempus AI, Inc. (“Tempus” or the “Company”) (NASDAQ: TEM) on behalf of Tempus stockholders. Our investigation concerns whether Tempus has violated the federal securities laws and/or engaged in other unlawful business practices.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”).

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.


Frøya, 5 June 2025: Reference is made to the stock exchange release from Kaldvík AS (the "Company") published on 4 June 2025 regarding a contemplated private placement to raise gross proceeds of the NOK equivalent of approximately EUR 46.2 million (the "Private Placement") by the issuance of new shares in the Company (the "Offer Shares"). The Company hereby announces that it has raised approximately NOK 532 million, equivalent to approximately EUR 46.2 million, in gross proceeds through a private placement of 38,011,050 new shares (the "New Shares") at a price per share of NOK 14 (the "Offer Price"). The Private Placement took place through an accelerated bookbuilding process managed by DNB Carnegie, a part of DNB Bank ASA ("DNB Carnegie") as Sole Global Coordinator and Joint Bookrunner and Arion Banki hf ("Arion") and Nordea Bank Abp, filial i Norge ("Nordea") as Joint Bookrunners for the Private Placement (jointly, the "Managers").

COOTAMUNDRA, Australia, June 04, 2025 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited (the “Company”) (NASDAQ: COOT), a manufacturer and seller of sustainable edible oils to customers globally, announced that it has received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) on May 27, 2025 stating that the Company was delinquent in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The Company previously filed a Form 12b-25 with the U.S. Securities and Exchange Commission on May 14, 2025, disclosing that it was unable to file the Form 10-Q within the prescribed time period without unreasonable effort or expense. The Nasdaq Letter provided that under Nasdaq rules, the Company has 60 calendar days to submit a plan to regain compliance with respect to the Delinquent Filing.